{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Day 94: Stringent Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Day 94: Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Day 94: Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Day 360: Stringent Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Day 360: Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Day 360: Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Day 360: Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Tumor responses were evaluated using appropriate imaging methods and were categorized according to the IMWG criteria, which includes the following response designations:\n\nComplete Response (CR): negative immunofixation on serum/urine, disappearance of soft tissue plasmacytomas, \\<5% plasma cells in bone marrow; Stringent CR (sCR): CR + normal free light chain (FLC) ratio and absence of clonal cells in bone marrow; Very Good Partial Response (VGPR): Serum/urine M-component detectable by immunofixation but not electropheresis OR ≥90% reduction in serum M-component + urine M-component \\<100 mg/24 hrs; Partial Response (PR): ≥50% reduction of serum M-protein and reduction in 24-hr urinary M-protein by ≥90% or to \\<200 mg/24 hrs Stable disease: not response or progression","groups":[{"description":"Includes all subjects who received at least 1 immunization with study drug and had a baseline and at least 1 post-baseline disease assessment.","id":"OG000","title":"Evaluable Analysis Set"}],"paramType":"NUMBER","populationDescription":"The Evaluable Analysis Set comprises all subjects who received at least 1 immunization with study drug and had a baseline and at least 1 post-baseline disease assessment.","reportingStatus":"POSTED","timeFrame":"At 3 and 12 months after auto-SCT","title":"Assessment of Tumor Response","type":"SECONDARY","unitOfMeasure":"participants"}